Tirzepatide → Vomiting — Audit-grade candidate

← All findings ⬇ Download signed audit packet

Ledger entry · candidate

Tirzepatide → Vomiting — Audit-grade candidate

Drug: tirzepatide · AE: Vomiting

Caliper validation of the submitted claim (drug=tirzepatide, AE=Vomiting). PRR = 2.00 (95% CI 1.90–2.12), n = 1194 cases. Pre-reg locked at submission; awaiting Adam's review before public ship.

Disproportionality

PRR: 2.003664387906243 (95% CI 1.90–2.12)
Yates χ²: 611.759507907894
Cases (case-drug + AE): n = 1194
Verdict: PASSES_ALL_GATES — PRR=2.00 (95% CI 1.90–2.12), n=1194 cases; flagged for clinical expert review, NOT for external escalation without manual verification

Top reactions in cohort

MedDRA PT	n
Vomiting	1157
Nausea	684
Diarrhoea	369
Off label use	178
Abdominal pain upper	120
Dehydration	92
Constipation	88
Decreased appetite	83

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: f8e23bca31f091a036687bacdc7db515ef06fbac